nVision’s Acquisition Positions Innovative Technology to Potentially Help Millions of Women

As the first and only device cleared by the FDA to collect cells from the fallopian tubes, the Mako 7 device, originally developed by nVision, a Fogarty Institute graduate, offers a potential platform for earlier detection of ovarian cancer. The company was recently acquired by Boston Scientific, as the device represents an exciting opportunity for the company to expand its focus on women’s health and provides a potential platform to improve care for women worldwide.

START TYPING AND PRESS ENTER TO SEARCH